The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).
Roberta Ruda
No relevant relationships to disclose
Luca Bertero
No relevant relationships to disclose
Elisa Trevisan
No relevant relationships to disclose
Andrea Pace
No relevant relationships to disclose
Carmine Maria Carapella
No relevant relationships to disclose
Cristina Dealis
No relevant relationships to disclose
Manuela Caroli
No relevant relationships to disclose
Marina Faedi
No relevant relationships to disclose
Chiara Bomprezzi
No relevant relationships to disclose
Riccardo Soffietti
No relevant relationships to disclose